Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis
– OpSCF is a novel monoclonal antibody directed against the inflammatory form of stem cell factor
News
Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformations is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 patients in the U.S.
SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma
Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies
Funds to support advancement of lead candidate, VIPER-101, to the clinic
ONCO, Inc. Announces Strategic Partnership with Oncora Medical to Launch Data-Driven Software Automation to Enhance Patient Care and Oncology Data Management.
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Immunome Reports Third Quarter 2023 Financial Results
– Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors
– Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO
– Bob Lechleider, M.D., appointed as Chief Medical Officer
– Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors
– Cash runway expected to extend into Q1 2026*
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
– Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
– ENB-003 in combination with KEYTRUDA (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC)
– Encouraging results support further development
– Expansion cohort in primary PROC and other refractory advanced cancers (ENB-003 + KEYTRUDA) to commence in 2024